Description
Voglibose is coming under the class of anti-diabetic drugs called Alpha Glucosidase Inhibitor.
Some set of diabetic patients include patients with Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose (IFG), in which glucose levels are above normal, but not high enough to label them as diabetics. Such patients are also prone to development of Diabetes Mellitus or diabetic complications later in life. Loss of early insulin secretion response, along with insulin resistance, results in development of Post-Prandial Hyperglycaemia (PPHG).
Voglibose is an alpha glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It delays the absorption of glucose at the intestine level and thereby prevent sudden surge of glucose after meal. Voglibose controls post-prandial plasma glucose (PPG).
This should be administered strictly with the prescription and advise of medical practitioners only.
